QQQ   311.09 (-0.20%)
AAPL   155.74 (+3.26%)
MSFT   262.53 (-0.78%)
META   192.45 (+1.95%)
GOOGL   107.11 (-0.58%)
AMZN   108.14 (-4.22%)
TSLA   197.34 (+4.82%)
NVDA   215.29 (-0.83%)
NIO   11.67 (-2.42%)
BABA   106.97 (-2.52%)
AMD   88.08 (-0.26%)
T   19.89 (-1.92%)
F   13.55 (-5.38%)
MU   63.52 (+0.55%)
CGC   3.04 (-3.18%)
GE   82.66 (-1.52%)
DIS   112.39 (-0.72%)
AMC   6.62 (+8.88%)
PFE   44.20 (-0.32%)
PYPL   87.08 (+0.14%)
NFLX   376.29 (+2.56%)
QQQ   311.09 (-0.20%)
AAPL   155.74 (+3.26%)
MSFT   262.53 (-0.78%)
META   192.45 (+1.95%)
GOOGL   107.11 (-0.58%)
AMZN   108.14 (-4.22%)
TSLA   197.34 (+4.82%)
NVDA   215.29 (-0.83%)
NIO   11.67 (-2.42%)
BABA   106.97 (-2.52%)
AMD   88.08 (-0.26%)
T   19.89 (-1.92%)
F   13.55 (-5.38%)
MU   63.52 (+0.55%)
CGC   3.04 (-3.18%)
GE   82.66 (-1.52%)
DIS   112.39 (-0.72%)
AMC   6.62 (+8.88%)
PFE   44.20 (-0.32%)
PYPL   87.08 (+0.14%)
NFLX   376.29 (+2.56%)
QQQ   311.09 (-0.20%)
AAPL   155.74 (+3.26%)
MSFT   262.53 (-0.78%)
META   192.45 (+1.95%)
GOOGL   107.11 (-0.58%)
AMZN   108.14 (-4.22%)
TSLA   197.34 (+4.82%)
NVDA   215.29 (-0.83%)
NIO   11.67 (-2.42%)
BABA   106.97 (-2.52%)
AMD   88.08 (-0.26%)
T   19.89 (-1.92%)
F   13.55 (-5.38%)
MU   63.52 (+0.55%)
CGC   3.04 (-3.18%)
GE   82.66 (-1.52%)
DIS   112.39 (-0.72%)
AMC   6.62 (+8.88%)
PFE   44.20 (-0.32%)
PYPL   87.08 (+0.14%)
NFLX   376.29 (+2.56%)
QQQ   311.09 (-0.20%)
AAPL   155.74 (+3.26%)
MSFT   262.53 (-0.78%)
META   192.45 (+1.95%)
GOOGL   107.11 (-0.58%)
AMZN   108.14 (-4.22%)
TSLA   197.34 (+4.82%)
NVDA   215.29 (-0.83%)
NIO   11.67 (-2.42%)
BABA   106.97 (-2.52%)
AMD   88.08 (-0.26%)
T   19.89 (-1.92%)
F   13.55 (-5.38%)
MU   63.52 (+0.55%)
CGC   3.04 (-3.18%)
GE   82.66 (-1.52%)
DIS   112.39 (-0.72%)
AMC   6.62 (+8.88%)
PFE   44.20 (-0.32%)
PYPL   87.08 (+0.14%)
NFLX   376.29 (+2.56%)
NASDAQ:ANIK

Anika Therapeutics - ANIK Stock Forecast, Price & News

$32.00
+0.16 (+0.50%)
(As of 02/3/2023 11:32 AM ET)
Add
Compare
Today's Range
$31.55
$32.14
50-Day Range
$27.89
$31.84
52-Week Range
$19.95
$33.18
Volume
8,249 shs
Average Volume
67,602 shs
Market Capitalization
$467.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
11.0% Downside
$28.50 Price Target
Short Interest
Healthy
3.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.57mentions of Anika Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

787th out of 1,029 stocks

Surgical & Medical Instruments Industry

83rd out of 107 stocks

ANIK stock logo

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Anika Therapeutics
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings
11/08/2022
Today
2/03/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
297
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$28.50
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
-10.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$4.13 million
Pretax Margin
-14.12%

Debt

Sales & Book Value

Annual Sales
$147.79 million
Cash Flow
$1.44 per share
Book Value
$19.89 per share

Miscellaneous

Free Float
14,167,000
Market Cap
$467.52 million
Optionable
Optionable
Beta
0.92

Social Links


Key Executives

  • Cheryl Renee Blanchard
    President, Chief Executive Officer & Director
  • Anne Nunes
    Vice President-Operations
  • Michael L. LevitzMichael L. Levitz
    Chief Financial Officer, Treasurer & EVP
  • Mira Leiwant
    VP-Quality, Regulatory & Clinical Affairs
  • Steven W. Ek
    Vice President-Research & Development













ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIK shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month target prices for Anika Therapeutics' shares. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they expect the company's share price to reach $28.50 in the next twelve months. This suggests that the stock has a possible downside of 10.5%.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2023?

Anika Therapeutics' stock was trading at $29.60 at the beginning of the year. Since then, ANIK stock has increased by 7.6% and is now trading at $31.84.
View the best growth stocks for 2023 here
.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 542,800 shares, a decrease of 17.3% from the December 31st total of 656,200 shares. Based on an average daily trading volume, of 101,400 shares, the short-interest ratio is currently 5.4 days. Approximately 3.8% of the company's stock are sold short.
View Anika Therapeutics' Short Interest
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.13. The biotechnology company had revenue of $40.26 million for the quarter, compared to analyst estimates of $36.56 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.49% and a negative net margin of 10.33%.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.33%), Assenagon Asset Management S.A. (0.33%), Ziegler Capital Management LLC (0.13%), Riverwater Partners LLC (0.07%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.06%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $31.84.

How much money does Anika Therapeutics make?

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $465.18 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Anika Therapeutics have?

The company employs 297 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 2/3/2023 by MarketBeat.com Staff